Potential therapeutics for SARS

Stable Identifier
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

No drug has yet (April 2020) been shown in a randomized double-blind placebo-controlled trial to prevent or reduce the severity of human infection with SARS-CoV-1 or SARS-CoV-2. Nevertheless, a large number of promising drug candidates have been identified on the basis of their efficacy in treatment of human infections with other RNA viruses or in diminishing cytokine storms and other pathologies due to destructive host reactions to viruses similar to SARS-CoV-1 and SARS-CoV-2. The interactions of these candidate drugs with their known viral and human protein targets are annotated.

In addition, some drugs that inhibit Cytochrome P450 (CYP) oxidoreductases have been shown to be effective in prolonging the plasma half-lives of antiviral drugs with acceptable side effects, and CYP inhibition by these drugs is annotated.

Finally, effects of any of these drugs on unrelated essential human proteins, that might limit their use in vivo are annotated.

Literature References
PubMed ID Title Journal Year
32205870 Coronavirus puts drug repurposing on the fast track

Harrison, C

Nat. Biotechnol. 2020
32256547 Clinical trials on drug repositioning for COVID-19 treatment

Rosa, SGV, Santos, WC

Rev. Panam. Salud Publica 2020
Name Identifier Synonyms
viral infectious disease DOID:934 Viral disease, virus infection, virus infection
Cite Us!